文章：

有多少脉络膜黑色素瘤患者符合接受新辅助全身治疗以进行钌-106近距离放射治疗的资格？

How Many Patients with Choroidal Melanoma Would Be Eligible for Neoadjuvant Systemic Therapy to Enable Ruthenium-106 Brachytherapy?

原文发布日期：16 September 2025

DOI: 10.3390/cancers17183022

类型: Article

开放获取: 是

英文摘要：

Background/Objectives: Neoadjuvant systemic therapy may enhance ocular and visual preservation, also prolonging life in patients with choroidal melanoma. We investigated how many choroidal melanomas would be eligible for such treatment to enable Ruthenium-106 brachytherapy. Methods: The cohort comprised 5859 patients treated for choroidal melanoma at the Liverpool Ocular Oncology Centre between 1993 and 2023. Results: If the objective is ocular conservation, then, after excluding tumors > 16 mm in diameter, involving disc and/or more than two clock hours of angle or iris, and/or extending extraocularly, approximately 60.5%, 65.1%, and 67.6% of patients would remain eligible for neoadjuvant systemic therapy, according to whether the maximum allowable tumor thickness is 8 mm, 10 mm or 12 mm, respectively. If the objective is preservation of 20/80 vision, and if exclusion criteria also include vision worse than 20/80 and tumor extension to within 3 mm of optic disc and/or fovea, then 31.0%, 33.2% and 34.1% of tumors would remain in the three tumor-thickness groups, respectively. Chromosome 3 loss would be found in approximately 33%, 52% and 56% of tumors measuring 11–12 mm, 13–14 mm and >14 mm, respectively. Conclusions: Based on the provided data and with effective neoadjuvant treatment, approximately two thirds of subjects with choroidal melanoma requiring enucleation could potentially become candidates for ruthenium-106 brachytherapy and as many as one third could also have the potential for preservation of useful vision.

摘要翻译： 

背景/目的：新辅助全身治疗可能增强脉络膜黑色素瘤患者的眼球和视力保留，同时延长生存期。本研究旨在探讨有多少脉络膜黑色素瘤患者符合接受此类治疗以实施钌-106近距离放射治疗的条件。方法：研究队列包括1993年至2023年间在利物浦眼肿瘤中心接受治疗的5859例脉络膜黑色素瘤患者。结果：若治疗目标为眼球保留，在排除直径>16毫米、累及视盘和/或超过两个钟点范围的房角或虹膜、和/或存在眼外扩展的肿瘤后，根据最大允许肿瘤厚度分别为8毫米、10毫米或12毫米的标准，分别约有60.5%、65.1%和67.6%的患者符合新辅助全身治疗条件。若治疗目标为保留20/80视力，且排除标准还包括视力差于20/80以及肿瘤扩展至视盘和/或黄斑中心凹3毫米范围内，则三个肿瘤厚度组中分别有31.0%、33.2%和34.1%的肿瘤符合条件。在肿瘤厚度为11-12毫米、13-14毫米和>14毫米的组别中，分别约有33%、52%和56%的肿瘤存在3号染色体缺失。结论：基于现有数据，若采用有效的新辅助治疗，约三分之二原本需要眼球摘除的脉络膜黑色素瘤患者可能成为钌-106近距离放射治疗的候选者，其中多达三分之一的患者还可能保留有效视力。

原文链接：

How Many Patients with Choroidal Melanoma Would Be Eligible for Neoadjuvant Systemic Therapy to Enable Ruthenium-106 Brachytherapy?